| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.05.
| MERIDIAN BIOSCIENCE INC - 10-Q, Quarterly Report | | - | SEC Filings |
| 02.05.
| XFRA DIVIDEND INFORMATION - 02.05.2012 - 3 | | 113 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 02.05.2012 EX DIVIDENDE GEHANDELT.
THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 02.05.2012.
INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT
4OT XFRA US6780491071...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 02.05.2012 - 3 | |
| 26.04.
| Meridian Bioscience Inc. Added to Premier's Molecular Rapid Qualitative Screening Portfolio | | 21 | Business Wire |
| The Premier
healthcare alliance today announced that Meridian Bioscience Inc. of
Cincinnati has been awarded a Technology Breakthroughs award for its
illumigene®...
Mehr lesen zu:
Meridian Bioscience Inc. Added to Premier's Molecular Rapid Qualitative Screening Portfolio | |
| 26.04.
| Meridian Bioscience Reports Record Second Quarter and First Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance | | 12 | Business Wire |
| Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
...
Mehr lesen zu:
Meridian Bioscience Reports Record Second Quarter and First Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance | |
| 12.04.
| Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C | | - | Benzinga.com |
| 12.04.
| Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C. difficile and Group B Streptococcus | | 33 | Business Wire |
| Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has signed a
new group purchasing agreement with the Premier healthcare alliance to
offer illumigene® C. difficile...
Mehr lesen zu:
Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C. difficile and Group B Streptococcus | |
| 12.04.
| Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter Financial Results on April 26 | | 42 | Business Wire |
| Meridian Bioscience, Inc. (NASDAQ: VIVO) has scheduled the release of
its 2012 second quarter financial results for Thursday, April 26 at
approximately 7:45 a.m. (Eastern).
...
Mehr lesen zu:
Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter Financial Results on April 26 | |
| 21.03.
| Meridian Bioscience (VIVO) Unit Gets TGA Clearance for Illumigene GBS Test | | - | StreetInsider.com |
| 27.02.
| Meridian Bioscience Receives FDA Clearance for New Legionella Test | | 36 | Business Wire |
| Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has
received FDA clearance from the U.S. Food and Drug Administration (FDA)
for TRU Legionella™, a new...
Mehr lesen zu:
Meridian Bioscience Receives FDA Clearance for New Legionella Test | |
| 09.02.
| MERIDIAN BIOSCIENCE INC - 10-Q, Quarterly Report | | - | SEC Filings |
| 31.01.
| XFRA DIVIDEND INFORMATION - 01.02.2012 - 2 | | 130 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 01.02.2012 EX DIVIDENDE GEHANDELT. THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 01.02.2012. INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT 4OT XFRA US6780491071...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 01.02.2012 - 2 | |
| 30.01.
| XFRA DIVIDEND INFORMATION - 01.02.2012 - 1 | | 125 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 31.01.2012 CUM DIVIDENDE UND AM 01.02.2012 EX DIVIDENDE GEHANDELT. THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 31.01.2012. THE EX-DIVIDEND DAY WILL BE 01.02.2012....
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 01.02.2012 - 1 | |
| 25.01.
| Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance | | 21 | Business Wire |
| Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
...
Mehr lesen zu:
Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance | |
| 27.12.
| Meridian Bioscience (VIVO) Gets FDA Approval for ImmunoCard C. difficile GDH | | - | StreetInsider.com |
| 27.12.
| Meridian Bioscience Receives FDA Clearance For ImmunoCard® C. difficile GDH Test | | 42 | Business Wire |
| Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today
announced it has received FDA clearance for a new Clostridium
difficile assay, ImmunoCard®
C. difficile...
Mehr lesen zu:
Meridian Bioscience Receives FDA Clearance For ImmunoCard® C. difficile GDH Test | |
| 12.12.
| Meridian Bioscience (VIVO) Gets FDA Clearance for Illumigene Platform GBS Test | | - | StreetInsider.com |
| 12.12.
| Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group B Streptococcus | | 18 | Business Wire |
| Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has received FDA clearance for a new molecular
diagnostic test for Group B Streptococcus...
Mehr lesen zu:
Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group B Streptococcus | |
